Group of Genitourinary (non-prostate), Central Nervous System (CNS) Tumours, Sarcomas and Tumours of unknown origin

CLINICAL RESEARCH

Over recent years, major advances have transformed the management of genitourinary (GU) malignancies, particularly through immunotherapy, antibody–drug conjugates (ADCs), targeted therapies, and radioligand approaches. Our group has played a central role in shaping these developments across bladder, kidney, prostate, and rare GU cancers through early-phase clinical trials, biomarker-driven strategies, and translational research.

In kidney cancer, we have contributed to the clinical development of immune-based combinations and HIF2α inhibitors, exploring novel combinations, earlier disease settings, and predictive biomarkers in collaboration with international partners. In bladder cancer, we are actively involved in phase I studies targeting FGFR and Nectin-4, innovative intravesical delivery strategies aimed at bladder preservation, and first-line combination approaches integrating multiple ADCs and immunotherapy. We also made a major contribution to IMvigor011, supporting the clinical integration of circulating tumor DNA as a precision oncology biomarker.

Beyond GU tumors, we have consolidated leadership in sarcoma, CNS tumors, and cancers of unknown primary (CUP), with investigator-initiated trials, national and European consortia, and real-world genomic and radiomic initiatives. Notable efforts include liquid biopsy–guided trials in GIST, first-in-class therapies for rare sarcomas, academic trials in glioblastoma, and AI-enabled imaging tools to support surgical and radiotherapy decision-making.

Our program is strongly patient-centered, integrating translational research, quality-of-life initiatives, survivorship, and dedicated care for adolescents and young adults (AYAs). Through national leadership roles, European projects, and sustained international collaboration, we continue to advance precision medicine approaches that improve outcomes across multiple cancer types.

Cristina Suárez

Group Leader

Biosketch

Rafael Morales

Senior Researcher

Biosketch

Claudia Valverde

Senior Researcher

Biosketch

Research Lines

Design and conduct investigator-initiated and collaborative clinical trials across GU cancers, sarcoma, CNS tumors, and CUP, spanning early and advanced disease stages.
Advance biomarker-driven precision oncology, including liquid biopsy, genomics, and imaging-based decision tools.
Strengthen translational platforms in kidney cancer, sarcoma/GIST, and CNS tumors through multidisciplinary task forces and biobanking.
Expand national and European clinical and research networks (CSUR, EURACAN, ACCELERATE) to improve access to innovative therapies.
Integrate patient-reported outcomes, survivorship, and quality-of-life research into clinical trial design and routine care.
Foster collaboration between academia, industry, and patient advocacy groups, and develop educational resources to empower patients and families.

Team

Group Leader

Cristina Suárez

Senior Investigator

Joan Carles

Medical Oncologists and Clinical Fellows

Carlo Cicala, Diego Gómez, Macarena González, David Marmolejo, Rafael Morales Barrera, César Serrano, Claudia Valverde, María Vieito

Clinical Nurse Specialist

Helena Palma

Publications

Most relevant scientific publications

Powles T, Kann AG, Castellano D, Gross-Goupil M, Nishiyama H, Bracarda S, Bjerggaard Jensen J, Makaroff L, Jiang S, Ku JH, Park SH, Reig Torras O, Ye D, Maruzzo M, Necchi A, Morales-Barrera R, Giunta EF, Lee JL, Tortora G, Ürün Y, Dolowy L, Erdem D, Pinto A, Grando F, Zou W, Assaf ZJ, Vuky J, Degaonkar V, Steinberg EE, Bellmunt J, Gschwend JE; IMvigor011 Investigators. ctDNA-Guided Adjuvant Atezolizumab in Muscle-Invasive Bladder Cancer. N Engl J Med. 2025 Dec 18;393(24):2395-2408.
Suarez C, Rojas C, Shin SJ, Yanez Weber P, Albiges L, Motzer R, Hammers H, Peer A, Lee JL, Miller WH, Waddell T, Neiman V, Keizman D, Zwenger Kloster A, Weickhardt A, Dziadziuszko R, Suttner L, Sharma M, Burgents JE, Powles T. Novel pembrolizumab-based treatments as first-line therapy in advanced clear-cell renal cell carcinoma: substudy 03A of the open-label, umbrella platform, phase I/II KEYMAKER-U03 trial. Ann Oncol. 2025 Oct 18. doi: 10.1016/j.annonc.2025.10.010.
Palmerini E, Meazza C, Tamburini A, Márquez-Vega C, Bisogno G, Fagioli F, Ferraresi V, Milano GM, Coccoli L, Rubio-San-Simón A, Gallego O, Llinares Riestra ME, Manzitti C, Mora J, Vaz-Salgado MÁ, Luksch R, Mata C, Pierini M, Carretta E, Cesari M, Paioli A, Marrari A, Scotlandi K, Serra M, Asaftei SD, Gambarotti M, Picci P, Ferrari S, Valverde C, Ibrahim T, Broto JM. Is There a Role for Mifamurtide in Nonmetastatic High-Grade Osteosarcoma? Results From the Italian Sarcoma Group (ISG/OS-2) and Spanish Sarcoma Group (GEIS-33) Trials. J Clin Oncol. 2025 Oct;43(28):3113-3122.
Serrano C, Bauer S, Blay JY, Casali PG, Cicala CM, Dei Tos AP, Digklia A, Gelderblom H, Italiano A, Jones RL, Kasper B, Kyriazoglou A, Le Loarer F, Martín-Broto J, Napolitano A, Rutkowski P, Stacchiotti S, Tap W, Thomas D, Thway K, Valverde C, van der Graaf WTA, Wardelmann E, Bovée JVMG. Guidelines for Next-Generation Sequencing in Sarcoma Diagnosis and Treatment: A Consensus Review. JAMA Oncol. 2025 Dec 1;11(12):1527-1537.
Heinrich MC, Jones RL, George S, Gelderblom H, Schöffski P, von Mehren M, Zalcberg JR, Kang YK, Razak AA, Trent J, Attia S, Le Cesne A, Siontis BL, Goldstein D, Boye K, Sanchez C, Steeghs N, Rutkowski P, Druta M, Serrano C, Somaiah N, Chi P, Reichmann W, Sprott K, Achour H, Sherman ML, Ruiz-Soto R, Blay JY, Bauer S. Ripretinib versus sunitinib in gastrointestinal stromal tumor: ctDNA biomarker analysis of the phase 3 INTRIGUE trial. Nat Med. 2024 Feb;30(2):498-506.
Powles T, Catto JWF, Galsky MD, Al-Ahmadie H, Meeks JJ, Nishiyama H, Vu TQ, Antonuzzo L, Wiechno P, Atduev V, Kann AG, Kim TH, Suárez C, Chang CH, Roghmann F, Özgüroğlu M, Eigl BJ, Oliveira N, Buchler T, Gadot M, Zakharia Y, Armstrong J, Gupta A, Hois S, van der Heijden MS; NIAGARA Investigators. Perioperative Durvalumab with Neoadjuvant Chemotherapy in Operable Bladder Cancer. N Engl J Med. 2024;391:1773-1786.
Choueiri TK, Powles T, Peltola K, de Velasco G, Burotto M, Suarez C, Ghatalia P, Iacovelli R, Lam ET, Verzoni E, Gümüş M, Stadler WM, Kollmannsberger C, Melichar B, Venugopal B, Gross-Goupil M, Poprach A, De Santis M, Schutz FA, Park SH, Nosov DA, Porta C, Lee JL, Garcia-Del-Muro X, Biscaldi E, Manneh Kopp R, Oya M, He L, Wang A, Perini RF, Vickery D, Albiges L, Rini B; LITESPARK-005 Investigators. Belzutifan versus Everolimus for Advanced Renal-Cell Carcinoma. N Engl J Med. 2024 Aug 22;391(8):710-721.
Sweis RF, Gajate P, Morales-Barrera R, Lee JL, Necchi A, de Braud F, Penel N, Grünwald V, Maruzzo M, Meran J, Ishida TC, Bao W, Zhou Y, Ellinghaus P, Rosenberg JE. Rogaratinib Plus Atezolizumab in Cisplatin-Ineligible Patients With FGFR RNA-Overexpressing Urothelial Cancer: The FORT-2 Phase 1b Nonrandomized Clinical Trial. JAMA Oncol. 2024 Nov;10(11):1565-1570.

All publications

Martin-Broto J, Diaz-Beveridge R, Moura D, Ramos R, Martinez-Trufero J, Carrasco I, Sebio A, González-Billalabeitia E, Gutierrez A, Fernandez-Jara J, Hernández-Vargas L, Cruz J, Valverde C, Hindi N. Phase Ib Study for the Combination of Doxorubicin, Dacarbazine, and Nivolumab as the Upfront Treatment in Patients With Advanced Leiomyosarcoma: A Study by the Spanish Sarcoma Group (GEIS). J Clin Oncol. 2025 Jan 20;43(3):297-307. doi: 10.1200/JCO.24.00358. Epub 2024 Oct 2. PMID: 39356980.
Cella D, Motzer RJ, Suarez C, Blum SI, Ejzykowicz F, Hamilton M, Wallace JF, Simsek B, Zhang J, Ivanescu C, Choueiri TK, Apolo AB. Plain language summary of quality of life in CheckMate 9ER: Cabozantinib plus nivolumab in advanced renal cell carcinoma. Future Oncol. 2025 Jan;21(2):181-194. doi: 10.1080/14796694.2024.2415786. Epub 2024 Oct 25. Erratum in: Future Oncol. 2025 Apr;21(10):1281. doi: 10.1080/14796694.2024.2432128. PMID: 39452894; PMCID: PMC11792805.
Motzer RJ, Bex A, Russo P, Tomita Y, Cutuli HJ, Rojas C, Gross-Goupil M, Schinzari G, Melichar B, Barthélémy P, Ruiz Garcia A, Sosman J, Grimm MO, Goh JC, Suarez C, Kollmannsberger CK, Nair SG, Shuch BM, Huang J, Simsek B, Spiridigliozzi J, Lee CW, van Kooten Losio M, Grünwald V. Adjuvant Nivolumab for Localized Renal Cell Carcinoma at High Risk of Recurrence After Nephrectomy: Part B of the Randomized, Placebo-Controlled, Phase III CheckMate 914 Trial. J Clin Oncol. 2025 Jan 10;43(2):189-200. doi: 10.1200/JCO.24.00773. Epub 2024 Sep 20. PMID: 39303200; PMCID: PMC11709003.
Cicala CM, Matito J, Quindos M, Gómez-Peregrina D, Romero-Lozano P, Fernández-Suárez P, Valverde C, González M, Landolfi S, Pérez-Albert P, Gros L, Vivancos A, Serrano C. Targeted Next-Generation Sequencing in Succinate Dehydrogenase-Deficient GI Stromal Tumor Identifies Actionable Alterations in the PI3K/mTOR Pathway. JCO Precis Oncol. 2025 Jan;9:e2400497. doi: 10.1200/PO-24-00497. Epub 2025 Jan 9. PMID: 39787462.
Calvo E, Doger B, Carles J, Peer A, Sarid D, Eigl BJ, Avadhani A, Yao D, Lin V, Wu S, Jaiprasart P, Loffredo J, Tamegnon M, Xu W, Xie H, Hansen AR. A first-in-human study of JNJ-70218902, a bispecific T-cell-redirecting antibody against TMEFF2 in metastatic castration-resistant prostate cancer. Oncologist. 2025 Jan 17;30(1):oyae313. doi: 10.1093/oncolo/oyae313. PMID: 39832129; PMCID: PMC11745015.
Palmerini E, Lopez Pousa A, Grignani G, Redondo A, Hindi N, Provenzano S, Sebio A, Lopez Martin JA, Valverde C, Martinez Trufero J, Gutierrez A, de Alava E, Aparisi Gomez MP, D’Ambrosio L, Collini P, Bazzocchi A, Moura DS, Ibrahim T, Stacchiotti S, Broto JM. Nivolumab and sunitinib in patients with advanced bone sarcomas: A multicenter, single-arm, phase 2 trial. Cancer. 2025 Jan 1;131(1):e35628. doi: 10.1002/cncr.35628. Epub 2024 Nov 14. PMID: 39540661; PMCID: PMC11694334.
Giani C, Salawu A, Ljevar S, Denu RA, Napolitano A, Palmerini E, Connolly EA, Ogura K, Wong DD, Scanferla R, Rosenbaum E, Bajpai J, Li ZC, Bae S, D’Ambrosio L, Bialick S, Wagner AJ, Lee ATJ, Koseła-Paterczyk H, Baldi GG, Brunello A, Lee YC, Loong HH, Boikos S, Campos F, Cicala CM, Maki RG, Hindi N, Figura C, Almohsen SS, Patel S, Jones RL, Ibrahim T, Karim R, Kawai A, Carey-Smith R, Boyle R, Taverna SM, Lazar AJ, Demicco EG, Bovee JVMG, Dei Tos AP, Fletcher C, Baumhoer D, Sbaraglia M, Schaefer IM, Miceli R, Gronchi A, Stacchiotti S. International Multicenter Retrospective Study From the Ultra-rare Sarcoma Working Group on Low-grade Fibromyxoid Sarcoma, Sclerosing Epithelioid Fibrosarcoma, and Hybrid Forms: Outcome of Primary Localized Disease. Am J Surg Pathol. 2025 Jan 1;49(1):27-34. doi: 10.1097/PAS.0000000000002330. Epub 2024 Oct 28. PMID: 39466087; PMCID: PMC11634151.
Gómez-Puerto D, Cicala CM, Valverde C, Serrano C. Emerging treatments for sarcoma: from 2024 onward. Expert Opin Emerg Drugs. 2025 Feb 3:1-18. doi: 10.1080/14728214.2025.2460525. Epub ahead of print. PMID: 39874592.
Staehler M, Basso U, Eymard JC, Barthelemy P, Bigot P, Laramas M, Rink M, Suarez C, Guillot A, Bedke J, Hamberg P, De Vivo R, Gajate P, Lázaro-Quintela M, Rastogi P, Perrot V, Qvick B, Dutailly P, Verzoni E, Procopio G. A Prospective Non-interventional Real-World Study of cabozantinib in Pretreated Patients With Advanced Renal Cell Carcinoma Refractory to Vascular Endothelial Growth Factor-Targeted Therapy (CASSIOPE). Clin Genitourin Cancer. 2025 Feb;23(1):102285. doi: 10.1016/j.clgc.2024.102285. Epub 2024 Nov 30. PMID: 39740313.
Livingston JA, Blay JY, Trent J, Valverde C, Agulnik M, Gounder M, Le Cesne A, McKean M, Wagner MJ, Stacchiotti S, Agresta S, Quintás-Cardama A, Reilly SA, Healy K, Hickman D, Zhao T, Ballesteros-Perez A, Khalil A, Collins MP, Piel J, Horrigan K, Lefkovith A, Innis S, Lazar AJ, Cote GM, Wagner AJ. A Phase I Study of FHD-609, a Heterobifunctional Degrader of Bromodomain-Containing Protein 9, in Patients with Advanced Synovial Sarcoma or SMARCB1-Deficient Tumors. Clin Cancer Res. 2025 Feb 17;31(4):628-638. doi: 10.1158/1078-0432.CCR-24-2583. PMID: 39660994.
Arce-Gallego S, Cresta Morgado P, Delgado-Serrano L, Simonetti S, Gonzalez M, Romero-Lozano P, Marmolejo D, Morales-Barrera R, Arnau GM, Semidey ME, Aguilar D, Cordoba-Terreros S, Mast R, de Albert M, Planas J, Cuadras M, Maldonado X, Suarez C, Casanova-Salas I, Figols M, Cros S, Mas A, Nonell L, Dienstmann R, Nuciforo P, Vivancos A, Llop-Guevara A, Carles J, Serra V, Mateo J. Homologous recombination repair status in metastatic prostate cancer by next-generation sequencing and functional immunofluorescence. Cell Rep Med. 2025 Feb 18;6(2):101937. doi: 10.1016/j.xcrm.2025.101937. Epub 2025 Feb 5. PMID: 39914385; PMCID: PMC11866514.
Albiges, Laurence; Gross-Goupil, Marine; Barthelemy, Philippe; Bamias, Aristotelis; Bedke, Jens; Bex, Axel; Fontes-Sousa, Mario; Grunwald, Viktor; Melichar, Bohuslav; Pickering, Lisa; Porta, Camillo; Procopio, Giuseppe; Rottey, Sylvie; Schmidinger, Manuela; Suarez, ; Velasco, Guillermo; Escudier, Bernard. Towards a Consensus on the Management of Metastatic Renal Cell Carcinoma: Insights from a European Delphi Study. Eur Urol Oncol. 08/02/2025. Doi: 10.1016/j.euo.2025.01.007.
Serrano C, Arregui M, Carrasco I, Hindi N, Martínez-Trufero J, Martínez-García J, Molina Á, Paisán A, Sánchez R, Sala MÁ. SEOM-GEIS Spanish clinical guidelines for the management of soft tissue sarcomas (2024). Clin Transl Oncol. 2025 Apr;27(4):1460-1471. doi: 10.1007/s12094-024-03842-5. Epub 2025 Feb 7. PMID: 39918719; PMCID: PMC12000159.
Talpin A, Maia A, Carpier JM, Kulakowski G, Aubergeon L, Kervevan J, Gaal C, Strozzi F, Billerey C, Amable L, Mersceman T, Garnier A, Oliveira C, Calderon C, Bachrouche D, Ventujol C, Bernard L, Manteau A, Martinez J, Bonnet M, Noguerol J, Laviolette K, Boullerot L, Malfroy M, Chevalier G, Adotevi O, Joffre O, Idbaih A, Vieito M, Ghiringhelli F, Stradella A, Tabatabai G, Burger MC, Mildenberger I, Herrlinger U, Reardon DA, Wick W, Gouttefangeas C, Bonny C, Chene L, Gamelas Magalhaes J. Mimicry-based strategy between human and commensal antigens for the development of a new family of immune therapies for cancer. J Immunother Cancer. 2025 Feb 20;13(2):e010192. doi: 10.1136/jitc-2024-010192. PMID: 39979071; PMCID: PMC11842988.Mimicry-based strategy between human and commensal antigens for the development of a new family of immune therapies for cancer.
Pal SK, Loriot Y, Necchi A, Singh P, Castellano D, Pagliaro L, Suarez C, McGregor BA, Vaishampayan UN, Hauke RJ, Powles T, Van Herpen CML, Courtney KD, Dreicer R, Sudhagoni R, Schwickart M, Andrianova S, Agarwal N. COSMIC-021 Phase Ib Study of Cabozantinib Plus Atezolizumab: Results from the Locally Advanced or Metastatic Urothelial Carcinoma Cohorts. J Clin Oncol. 2025 May 10;43(14):1650-1662. doi: 10.1200/JCO-24-01675. Epub 2025 Feb 18. PMID: 39965176; PMCID: PMC12058374.
Ortega-Bertran S, Fernández-Rodríguez J, Magallón-Lorenz M, Zhang X, Creus-Bachiller E, Diazgranados AP, Uriarte-Arrazola I, Mazuelas H, Blanco I, Valverde C, Carrió M, Villanueva A, De Raedt T, Romagosa C, Gel B, Salvador H, Ferrer M, Lázaro C, Serra E. Triple Combination of MEK, BET, and CDK Inhibitors Significantly Reduces Human Malignant Peripheral Nerve Sheath Tumors in Mouse Models. Clin Cancer Res. 2025 Mar 3;31(5):907-920. doi: 10.1158/1078-0432.CCR-24-2807. PMID: 39786423; PMCID: PMC11873804.
Matsubara N, Azad AA, Agarwal N, Saad F, De Giorgi U, Joung JY, Fong PCC, Jones RJ, Zschäbitz S, Oldenburg J, Shore ND, Dunshee C, Carles J, Fay AP, Cislo P, Chang J, Healy CG, Niyazov A, Fizazi K. First-line talazoparib plus enzalutamide versus placebo plus enzalutamide for metastatic castration-resistant prostate cancer: patient-reported outcomes from the randomised, double-blind, placebo-controlled, phase 3 TALAPRO-2 trial. Lancet Oncol. 2025 Apr;26(4):470-480. doi: 10.1016/S1470-2045(25)00030-0. PMID: 40179906.
Fizazi K, Azad AA, Matsubara N, Carles J, Fay AP, De Giorgi U, Joung JY, Fong PCC, Voog E, Jones RJ, Shore ND, Dunshee C, Zschäbitz S, Oldenburg J, Ye D, Lin X, Healy CG, Di Santo N, Laird AD, Zohren F, Agarwal N. Talazoparib plus enzalutamide versus placebo plus enzalutamide for patients with advanced prostate cancer and changes in specific DNA repair genes: a plain language summary of the results from the TALAPRO-2 study. Future Oncol. 2025 Mar;21(6):637-652. doi: 10.1080/14796694.2025.2449754.
Pal SK, Bernard-Tessier A, Grell P, Gao X, Kotecha RR, Picus J, de Braud F, Takahashi S, Wong A, Suárez C, Otero JA, Kundamal N, Yang X, Sharaby S, Roy M, Barzaghi-Rinaudo P, Tannir NM. A Phase I Dose-Escalation Study of the HIF-2 Alpha Inhibitor DFF332 in Patients with Advanced Clear-Cell Renal Cell Carcinoma. Clin Cancer Res. 2025 May 15;31(10):1847-1855. doi: 10.1158/1078-0432.CCR-24-2618. PMID: 40043000; PMCID: PMC12079095.
Panian J, Zhong C, Choi SH, Ly K, Quinn R, Ferrier E, Saad E, Saliby RM, Malvar C, Pal S, Ebrahimi H, Tran B, Jude E, Lalani AK, Suarez C, Velasco G, Kanesvaran R, Zarba M, Liow E, El Hajj Chehade R, Choueiri TK, Heng DYC, McKay RR. Efficacy of Treatments After Lenvatinib in Patients with Advanced Renal Cell Carcinoma. Eur Urol Focus. 2025 Mar;11(2):279-286. doi: 10.1016/j.euf.2024.11.011. Epub 2024 Dec 7. PMID: 39648092.
Pal SK, Powles T, Kanesvaran R, Molina-Cerrillo J, Feldman DR, Barata P, Liu M, Bhatt A, Wang Z, Nandoskar P, Suarez C. STELLAR-304: a phase III study of zanzalintinib (XL092) plus nivolumab in advanced non-clear cell renal cell carcinoma. Future Oncol. 2025 Mar;21(7):787-794. doi: 10.1080/14796694.2025.2458395. Epub 2025 Feb 26. PMID: 40008409; PMCID: PMC11916370.
Sahai E, Wang H, Kok M, Wu CJ, Shen L, Carpten J, Serrano C, Venkataramani V. Many paths, one destination: Bridging the gap in cancer care. Cancer Cell. 2025 Apr 14;43(4):577-580. doi: 10.1016/j.ccell.2025.03.026. PMID: 40233716.
Guerrero M, Proaño-Pérez E, Serrano-Candelas E, García-Valverde A, Carrillo-Rodríguez B, Rosell J, Serrano C, Martin M. Preclinical study of microphthalmia-associated transcription factor inhibitor ML329 in gastrointestinal stromal tumor growth. Mol Ther Oncol. 2025 Apr 14;33(2):200983. doi: 10.1016/j.omton.2025.200983. PMID: 40343114; PMCID: PMC12060441.
Grünwald V, McKay RR, Buchler T, Eto M, Park SH, Takagi T, Zanetta S, Keizman D, Suárez C, Négrier S, Lee JL, Santini D, Bedke J, Staehler M, Kollmannsberger C, Choueiri TK, Motzer RJ, Burgents JE, Xie R, Okpara CE, Powles T. Clinical outcomes by baseline metastases in patients with renal cell carcinoma treated with lenvatinib plus pembrolizumab versus sunitinib: Post hoc analysis of the CLEAR trial. Int J Cancer. 2025 Apr 1;156(7):1326-1335. doi: 10.1002/ijc.35288. Epub 2024 Dec 30. PMID: 39739622; PMCID: PMC11789451.
Powles T, Choueiri TK, Albiges L, Peltola K, de Velasco G, Burotto M, Suarez C, Ghatalia P, Iacovelli R, Lam ET, Verzoni E, Gümüş M, Stadler WM, Kollmannsberger C, Melichar B, Venugopal B, Gross-Goupil M, Poprach A, De Santis M, Rizzo M, Shinde R, Saretsky TL, He L, Perini RF, Vickery D, Rini B. Health-related quality of life with belzutifan versus everolimus for advanced renal cell carcinoma (LITESPARK-005): patient-reported outcomes from a randomised, open-label, phase 3 trial. Lancet Oncol. 2025 Apr;26(4):491-502. doi: 10.1016/S1470-2045(25)00032-4. Epub 2025 Mar 17. PMID: 40112850.
Nuñez Hernández I, Gómez Palmero C, Delgado JR, Nuño A, Sala González MÁ, González Ageitos A, Aguilar H, Ayala de Miguel P, Condori E, Díaz Beveridge R, Martínez García J, Marquina G, Varela-Pose V, Veas Rodríguez J, Serrano C. Evaluation of the effectiveness and safety of avapritinib in real-world Spanish cases with gastrointestinal stromal tumor and D842V-PDGFRA mutation. Oncologist. 2025 May 8;30(5):oyaf062. doi: 10.1093/oncolo/oyaf062. PMID: 40349140; PMCID: PMC12065942.
Statz-Geary K, Elliott A, Bialick S, Serrano C, von Mehren M, Oberley M, Espejo-Freire AP, Barreto Coelho P, Costa PA, D’Amato GZ, Jonczak E, Trent JC, Montgomery E, Lombard D, Rosenberg A, Dhir A. DNA Damage Repair Pathway Alterations and Immune Landscape Differences in Pediatric/Adolescent, Young Adult (AYA) and Adult Sarcomas. Cancers (Basel). 2025 Jun 12;17(12):1962. doi: 10.3390/cancers17121962. PMID: 40563612; PMCID: PMC12191036.
Morfouace M, Bielle F, Razis E, Estrade F, Rubio A, Bautista F, de Rojas T, Vieito M, Meade S, Sanson M, Marques AC, Preusser M, Hatcher H, Balasubramanian GP, Pineda E, D’Hondt L, Duerinck J, Michotte A, Mawrin C, Ribalta T, Marucci G, Golfinopoulos V, Pfister SM, Jones DT, McCabe MG. Molecular analysis of adolescent and young adult high grade gliomas in the SPECTA-AYA study: Poorly characterised tumours with frequent germline alterations. Eur J Cancer. 2025 Jun 18;223:115493. doi: 10.1016/j.ejca.2025.115493. Epub 2025 May 13. PMID: 40393126.
Agarwal N, Azad AA, Carles J, Matsubara N, Oudard S, Saad F, Merseburger AS, Soares A, McGregor BA, Zurawski B, Tsiatas M, North S, Bondarenko I, Alfie M, Bournakis E, Antonuzzo L, Evilevitch L, Simmons A, Wang F, Ferraldeschi R, Nandoskar P, Pal SK. Cabozantinib plus atezolizumab in metastatic prostate cancer (CONTACT-02): final analyses from a phase 3, open-label, randomised trial. Lancet Oncol. 2025 Jul;26(7):860-876. doi: 10.1016/S1470-2045(25)00209-8. Epub 2025 Jun 13. PMID: 40523369.
Romandini D, Sobczuk P, Cicala CM, Serrano C. Next questions on gastrointestinal stromal tumors: unresolved challenges and future directions. Curr Opin Oncol. 2025 Jul 1;37(4):358-364. doi: 10.1097/CCO.0000000000001145. Epub 2025 Apr 4. PMID: 40207474.
Cicala CM, Bauer S, Heinrich MC, Serrano C. Gastrointestinal Stromal Tumor: Current Approaches and Future Directions in the Treatment of Advanced Disease. Hematol Oncol Clin North Am. 2025 Aug;39(4):773-784. doi: 10.1016/j.hoc.2025.04.006. Epub 2025 May 13. PMID: 40368739; PMCID: PMC12416134.
Fizazi K, Azad AA, Matsubara N, Carles J, Fay AP, De Giorgi U, Young Joung J, Fong PCC, Voog E, Jones RJ, Shore ND, Dunshee C, Zschäbitz S, Oldenburg J, Ye D, Lin X, Kalac M, Douglas Laird A, Kennedy D, Agarwal N. Talazoparib plus enzalutamide in men with HRR-deficient metastatic castration-resistant prostate cancer: final overall survival results from the randomised, placebo-controlled, phase 3 TALAPRO-2 trial. Lancet. 2025 Aug 2;406(10502):461-474. doi: 10.1016/S0140-6736(25)00683-X. Epub 2025 Jul 16. PMID: 40683287.
Suárez C, Reig Torras Ò, Morales Barrera R, Rodríguez Sánchez Á, Anguera Palacios G, Manshino AMB, Fernández Núñez N, Méndez Vidal MJ, García Carbonero I, Fernández Calvo O, Gironés Sarrió R, Crespo Herrero G, Afonso Afonso J, Juan Fita MJ, Gumà Padró J, Lázaro Quintela M, Rodriguez-Vida A, Hernández Pérez C, Medina Colmenero A, Collado Martín R, Garcías de España C, Molins Palau C, Martínez Ortega E, Gallardo E; SPRWEC Study investigators. Effectiveness and Safety of Cabozantinib Treatment in Patients with Advanced Renal Cell Carcinoma in Spanish and Portuguese Real-world Practice: The SOGUG-SPRWEC Study. Clin Genitourin Cancer. 2025 Oct;23(5):102402. doi: 10.1016/j.clgc.2025.102402. Epub 2025 Jul 23. PMID: 40830022.
Palomino Escobar LC, Díaz-Mejía N, Maldonado X, Semidey ME, Mast R, Trilla E, Morales R, Carles J. Combined neuroendocrine carcinoma of the penis: clinical, pathological and therapeutic insights. BMJ Case Rep. 2025 Jul 1;18(7):e265257. doi: 10.1136/bcr-2025-265257.
Palomino Escobar LC, Díaz-Mejía N, Maldonado X, Semidey ME, Mast R, Trilla E, Morales R, Carles J. Combined neuroendocrine carcinoma of the penis: clinical, pathological and therapeutic insights. BMJ Case Rep. 2025 Jul 1;18(7):e265257. doi: 10.1136/bcr-2025-265257. PMID: 40592597.
Whittle JR, Vieito M, Rohrberg K, Rodriguez-Ruiz ME, Castanon E, Mellinghoff IK, Van Linde M, Cloughesy T, Reardon DA, Chong RA, Rosenthal M, Wick A, Waldhauer I, Henkel N, Romagnoli B, Wolowski V, Dey S, Heil F, Heichinger C, Flinn N, Gou JP, Smith L, Prince F, Derks M, Roller A, Schiff C, Schneider M, Mason W. First-in-human study of an EGFRvIII x CD3 T cell bispecific antibody in the treatment of newly diagnosed glioblastoma. Neurooncol Adv. 2025 Jul 18;7(1):vdaf160. doi: 10.1093/noajnl/vdaf160. PMID: 40842640; PMCID: PMC12365897.
Grünwald V, Bex A, Rottey S, Suárez C, Procopio G, Velasco G, Melichar B, Bedke J, Pickering L, Fontes-Sousa M, Schmidinger M, Bamias A, Gross-Goupil M, Porta C, Barthélémy P, Escudier B, Albiges L. Current status of adjuvant immunotherapy and relapse management in renal cell carcinoma: Insights from a European delphi study. Eur J Cancer. 2025 Jul 25;225:115569. doi: 10.1016/j.ejca.2025.115569. Epub 2025 Jun 7. PMID: 40516320.
Bergmann L, Albiges L, Ahrens M, Gross-Goupil M, Boleti E, Gravis G, Fléchon A, Grimm MO, Bedke J, Barthélémy P, Castellano D, Mellado B, Ivanyi P, Rottey S, Flörcken A, Suarez C, Maroto P, Grünwald V, Oosting SF, Kopecky J, Zschäbitz S, Boegemann M, Buchler T, Niegisch G, Goebell PJ, Waddell T, Joly F, Priou F, Retz M, Siemer S, Zimmermann U, Deckbar D, Burkholder I, Hartmann A, Haanen JB; Interdisciplinary Renal Cell Carcinoma Working Group of the DKG (IAGN). Prospective randomized phase-II trial of ipilimumab/nivolumab versus standard of care in non-clear cell renal cell cancer – results of the SUNNIFORECAST trial. Ann Oncol. 2025 Jul;36(7):796-806. doi: 10.1016/j.annonc.2025.03.016. Epub 2025 Apr 1. PMID: 40180121.
Powles T, Choueiri TK, Albiges L, Peltola K, de Velasco G, Burotto M, Suarez C, Ghatalia P, Iacovelli R, Lam ET, Verzoni E, Gümüş M, Stadler WM, Kollmannsberger C, Melichar B, Venugopal B, Gross-Goupil M, Poprach A, De Santis M, Rizzo M, Shinde R, Saretsky TL, He L, Perini RF, Vickery D, Rini B. Health-related quality of life with belzutifan versus everolimus for advanced renal cell carcinoma (LITESPARK-005): patient-reported outcomes from a randomised, open-label, phase 3 trial. Lancet Oncol. 2025 Apr;26(4):491-502. doi: 10.1016/S1470-2045(25)00032-4. Epub 2025 Mar 17. PMID: 40112850.
Haddox CL, Papke DJ Jr, Serrano C. Leiomyosarcoma Therapeutic Approaches and Future Directions. Hematol Oncol Clin North Am. 2025 Aug;39(4):785-804. doi: 10.1016/j.hoc.2025.04.007. Epub 2025 May 22. PMID: 40410055.
Palmerini E, Meazza C, Tamburini A, Márquez-Vega C, Bisogno G, Fagioli F, Ferraresi V, Milano GM, Coccoli L, Rubio-San-Simón A, Gallego O, Llinares Riestra ME, Manzitti C, Mora J, Vaz-Salgado MÁ, Luksch R, Mata C, Pierini M, Carretta E, Cesari M, Paioli A, Marrari A, Scotlandi K, Serra M, Asaftei SD, Gambarotti M, Picci P, Ferrari S, Valverde C, Ibrahim T, Broto JM. Is There a Role for Mifamurtide in Nonmetastatic High-Grade Osteosarcoma? Results From the Italian Sarcoma Group (ISG/OS-2) and Spanish Sarcoma Group (GEIS-33) Trials. J Clin Oncol. 2025 Oct;43(28):3113-3122. doi: 10.1200/JCO-25-00210. Epub 2025 Aug 18. PMID: 40825172; PMCID: PMC12456199.
Vinciguerra A, Caspani F, Valentini M, Camarda AM, Provenzano S, Wang EW, Meço C, Ferrari M, Surda P, Harrabi S, Campos FAB, Broto JM, Guadagnolo BA, Navarria P, Hosni A, Hindi N, Italiano A, Trifiletti DM, Kasper B, Verillaud B, Schreiber A, Castelnuovo P, Nicolai P, Dallan I, Chacon M, Su SY, Thariat J, Valverde C, Lechner M, Blay JY, Fiore MR, Eloy JA, Brahmi M, Palmer JN, Oliden VC, Greto D, Lugowska I, Tos APD, van Zele T, Psaltis AJ, Casali PG, Dufresne A, Sangalli C, Georgalas C, Orlandi E, Wormald PJ, Herman P, Carrau R, Hanna EY, Licitra L, Turri-Zanoni M, Battaglia P. Sinonasal Sarcomas Management: An International Consensus Statement. Int Forum Allergy Rhinol. 2026 Jan;16(1):55-69. doi: 10.1002/alr.70038. Epub 2025 Sep 30. PMID: 41025537; PMCID: PMC12761347.
Kyriazoglou A, Zając A, Valverde C, Czarnecka AM, Błoński P, Romagosa C, Seliga KA, Koulouridi A, Mala A, Wągrodzki M, Silva TM, Witczak M, Ługowska I, Rosińska M, Álvarez R, Aguirre M, Tysarowski A, Kokkali S, Georgoulias V, Serrano C, Rutkowski P, Boukovinas I. Exploring the impact of NGS on diagnostics and treatment of sarcoma: insights from real-world data across multiple institutions in Europe. ESMO Open. 2025 Sep;10(9):105577. doi: 10.1016/j.esmoop.2025.105577. Epub 2025 Sep 11. PMID: 40939238; PMCID: PMC12529307.
Proaño-Pérez E, Serrano-Candelas E, Guerrero M, Gómez-Peregrina D, Llorens C, Soriano B, Gámez-Valero A, Herrero-Lorenzo M, Martí E, Serrano C, Martin M. MITF regulates autophagy and extracellular vesicle cargo in gastrointestinal stromal tumors. Mol Biomed. 2025 Oct 31;6(1):92. doi: 10.1186/s43556-025-00329-9. PMID: 41168571; PMCID: PMC12575911.
Suarez C, Rojas C, Shin SJ, Yanez Weber P, Albiges L, Motzer R, Hammers H, Peer A, Lee JL, Miller WH, Waddell T, Neiman V, Keizman D, Zwenger Kloster A, Weickhardt A, Dziadziuszko R, Suttner L, Sharma M, Burgents JE, Powles T. Novel pembrolizumab-based treatments as first-line therapy in advanced clear-cell renal cell carcinoma: substudy 03A of the open-label, umbrella platform, phase I/II KEYMAKER-U03 trial. Ann Oncol. 2026 Feb;37(2):229-240. doi: 10.1016/j.annonc.2025.10.010. Epub 2025 Oct 18. PMID: 41115468.
Dienstmann R, Vivancos A, Nuciforo P, Aguilar S, Ruiz-Pace F, Viaplana C, Gonzalez J, Fite B, Pedrola A, Elez E, Saura C, Felip E, Macarulla T, Capdevila J, Fariñas-Madrid L, Carles J, Mateo J, Muñoz-Cosuelo E, Balmaña J, Braña I, Garralda E, Tabernero J. Genomic actionability and matched targeted therapy in a decade-long institutional precision medicine program for solid tumors. ESMO Open. 2025 Nov;10(11):105888. doi: 10.1016/j.esmoop.2025.105888. Epub 2025 Nov 6. PMID: 41202500; PMCID: PMC12639418
Azad AA, Fizazi K, Matsubara N, Saad F, De Giorgi U, Joung JY, Fong PCC, Jones RJ, Zschäbitz S, Oldenburg J, Shore ND, Dunshee C, Carles J, Fay AP, Lin X, DeAnnuntis L, Di Santo N, Zielinski MA, Agarwal N. Talazoparib plus enzalutamide in metastatic castration-resistant prostate cancer: Safety analyses from the randomized, placebo-controlled, phase III TALAPRO-2 study. Eur J Cancer. 2024 Dec;213:115078. doi: 10.1016/j.ejca.2024.115078. Epub 2024 Oct 20. Erratum in: Eur J Cancer. 2026 Jan;232:116106. doi: 10.1016/j.ejca.2025.116106. PMID: 39486165.
Carles J, Tombal B, Hussain M, Saad F, Fizazi K, Montesa Pino Á, Méndez-Vidal MJ, Rodriguez-Vida A, Castellano D, Borrega P, Adorjan P, Moretones C, Dissanayake M, Smith MR. Age-related Efficacy and Safety of Darolutamide Plus Androgen-deprivation Therapy and Docetaxel in Patients with Metastatic Hormone-sensitive Prostate Cancer: A Subgroup Analysis of the Phase 3 ARASENS Trial. Eur Urol Oncol. 2025 Nov 4:S2588-9311(25)00255-X. doi: 10.1016/j.euo.2025.10.001. Epub ahead of print. PMID: 41193271.
Spanggaard I, Matrana M, Rocha Lima C, Mahipal A, Vieito M, Hervieu A, Goyal L, Rodón J, Veronese ML, Oliveira N, Li X, Schaffer M, Kesari S. Pemigatinib for previously treated metastatic or unresectable central nervous system tumors with fibroblast growth factor receptor mutations or rearrangements: FIGHT-207 results. Oncologist. 2025 Nov 11;30(11):oyaf272. doi: 10.1093/oncolo/oyaf272. PMID: 41100064; PMCID: PMC12640119.
de Torres CS, Trallero-Araguas E, Marmolejo D, Hermida JMU, Mejía ND, Baselga PM, Geng-Cahuayme AAA, Catalan L, González M, Morales-Barrera R, Carles J, Gallardo E, Suárez C. Balancing risks and benefits of immune checkpoint inhibitors in patients with pre-existing immune-mediated inflammatory diseases: A comprehensive review. Crit Rev Oncol Hematol. 2025 Dec;216:105000. doi: 10.1016/j.critrevonc.2025.105000. Epub 2025 Oct 30. PMID: 41176078.
Serrano C, Bauer S, Blay JY, Casali PG, Cicala CM, Dei Tos AP, Digklia A, Gelderblom H, Italiano A, Jones RL, Kasper B, Kyriazoglou A, Le Loarer F, Martín-Broto J, Napolitano A, Rutkowski P, Stacchiotti S, Tap W, Thomas D, Thway K, Valverde C, van der Graaf WTA, Wardelmann E, Bovée JVMG. Guidelines for Next-Generation Sequencing in Sarcoma Diagnosis and Treatment: A Consensus Review. JAMA Oncol. 2025 Dec 1;11(12):1527-1537. doi: 10.1001/jamaoncol.2025.3608. PMID: 41100097.
de Torres CS, Trallero-Araguas E, Marmolejo D, Hermida JMU, Mejía ND, Baselga PM, Geng-Cahuayme AAA, Catalan L, González M, Morales-Barrera R, Carles J, Gallardo E, Suárez C. Balancing risks and benefits of immune checkpoint inhibitors in patients with pre-existing immune-mediated inflammatory diseases: A comprehensive review. Crit Rev Oncol Hematol. 2025 Dec;216:105000. doi: 10.1016/j.critrevonc.2025.105000. Epub 2025 Oct 30. PMID: 41176078.
Brandariz J, de Llobet L, Esquefa V, Aguilar D, Salca A, Arce-Gallego S, Cresta Morgado P, Sole A, Agundez L, Mir G, Castro N, Casals T, Oliveira A, Casanova-Salas I, Malumbres M, Carles J, Morellá-Aucejo Á, Bernardos A, Martínez-Máñez R, Mateo J, Herranz N. Harnessing Senolytics and PARP Inhibition to Expand the Antitumor Activity of CDK4/6 Inhibitors in Prostate Cancer. Mol Cancer Ther. 2025 Dec 2;24(12):1959-1976. doi: 10.1158/1535-7163.MCT-24-0903. PMID: 40601842.
Mezquita L, Vicente-Herrero MT, Cruz P, de la Torre MVRÍ, Hidalgo-Coloma J, García LC, Gallego O, Calvo A, Martínez K, Pérez-Altozano J, Molina R, García-Pardo M, Gutiérrez-Sainz L, Moreno-Atahonero E, Oré-Arce M, Serrano C, Terradillos-García MJ, Valero MR, Reinoso-Barbero L, Rodríguez CA, Calvo-Cerrada B; SEOM – Environmental, Occupational Cancer Working Group, the AEEMT – Functional Group on Cancer, Work. SEOM-AEEMT consensus on occupational cancer and cancer-associated disability. Clin Transl Oncol. 2025 Sep 16. doi: 10.1007/s12094-025-04037-2. Epub ahead of print. PMID: 40956506.Voss MH, Gurney H, Atduev V, Suarez C, Climent MA, Pook D, Tomczak P, Barthélémy P, Lee JL, Nalbandian T, Stus V, Ferguson T, Wiechno P, Gokmen E, Lacombe L, Gedye C, Cornell J, Sharma M, Burgents JE, Albiges L. First-line Pembrolizumab Plus Lenvatinib for Advanced Non-clear-cell Renal Cell Carcinoma: Updated Results from the Phase 2 KEYNOTE-B61 Trial. Eur Urol. 2025 Dec;88(6):614-624. doi: 10.1016/j.eururo.2025.05.019. Epub 2025 Jul 24. PMID: 40707309.
de Torres CS, Trallero-Araguas E, Marmolejo D, Hermida JMU, Mejía ND, Baselga PM, Geng-Cahuayme AAA, Catalan L, González M, Morales-Barrera R, Carles J, Gallardo E, Suárez C. Balancing risks and benefits of immune checkpoint inhibitors in patients with pre-existing immune-mediated inflammatory diseases: A comprehensive review. Crit Rev Oncol Hematol. 2025 Dec;216:105000. doi: 10.1016/j.critrevonc.2025.105000. Epub 2025 Oct 30. PMID: 41176078.
Heinrich MC, Jones RL, George S, Gelderblom H, Schöffski P, von Mehren M, Zalcberg JR, Kang YK, Razak AA, Trent J, Attia S, Le Cesne A, Siontis BL, Goldstein D, Boye K, Sanchez C, Steeghs N, Rutkowski P, Druta M, Serrano C, Somaiah N, Chi P, Reichmann W, Sprott K, Achour H, Sherman ML, Ruiz-Soto R, Blay JY, Bauer S. Ripretinib versus sunitinib in gastrointestinal stromal tumor: ctDNA biomarker analysis of the phase 3 INTRIGUE trial. Nat Med. 2024 Feb;30(2):498-506.
Powles T, Catto JWF, Galsky MD, Al-Ahmadie H, Meeks JJ, Nishiyama H, Vu TQ, Antonuzzo L, Wiechno P, Atduev V, Kann AG, Kim TH, Suárez C, Chang CH, Roghmann F, Özgüroğlu M, Eigl BJ, Oliveira N, Buchler T, Gadot M, Zakharia Y, Armstrong J, Gupta A, Hois S, van der Heijden MS; NIAGARA Investigators. Perioperative Durvalumab with Neoadjuvant Chemotherapy in Operable Bladder Cancer. N Engl J Med. 2024;391:1773-1786.
Choueiri TK, Powles T, Peltola K, de Velasco G, Burotto M, Suarez C, Ghatalia P, Iacovelli R, Lam ET, Verzoni E, Gümüş M, Stadler WM, Kollmannsberger C, Melichar B, Venugopal B, Gross-Goupil M, Poprach A, De Santis M, Schutz FA, Park SH, Nosov DA, Porta C, Lee JL, Garcia-Del-Muro X, Biscaldi E, Manneh Kopp R, Oya M, He L, Wang A, Perini RF, Vickery D, Albiges L, Rini B; LITESPARK-005 Investigators. Belzutifan versus Everolimus for Advanced Renal-Cell Carcinoma. N Engl J Med. 2024 Aug 22;391(8):710-721.
Sweis RF, Gajate P, Morales-Barrera R, Lee JL, Necchi A, de Braud F, Penel N, Grünwald V, Maruzzo M, Meran J, Ishida TC, Bao W, Zhou Y, Ellinghaus P, Rosenberg JE. Rogaratinib Plus Atezolizumab in Cisplatin-Ineligible Patients With FGFR RNA-Overexpressing Urothelial Cancer: The FORT-2 Phase 1b Nonrandomized Clinical Trial. JAMA Oncol. 2024 Nov;10(11):1565-1570.
DM Geynisman; M Burotto; C Porta; C Suarez; MT Bourlon; V Del Tejo; EX Du; X Yang; SR Sendhil; KA Betts; S Huo. Grade 3/4 Adverse Event Costs of Immuno-oncology Combination Therapies for Previously Untreated Advanced Renal Cell Carcinoma. Oncologist.28 – 1, pp. 72 – 79. 18/01/2023. ISSN 1549490X. DOI: 10.1093/oncolo/oyac186
Matthew S. Ernst; Vishal Navani; J. Connor Wells; Frede Donskov; Naveen Basappa; Chris Labaki; Sumanta K. Pal; Luis Meza; Lori A. Wood; D. Scott Ernst; Bernadett Szabados; Rana R. McKay; Francis Parnis; Cristina Suarez; Takeshi Yuasa; Aly-Khan Lalani; Ajjai Alva; Georg A Bjarnason; Toni K. Choueiri; Daniel Y.C. Henga. Outcomes for International Metastatic Renal Cell Carcinoma Database Consortium Prognostic Groups in Contemporary First-line Combination Therapies for Metastatic Renal Cell Carcinoma. European Urology. 26/01/2023. ISSN 0302-2838. DOI: 10.1016/j.eururo.2023.01.001
Suarez, Cristina; Vieito, Maria; Valdivia, Augusto; Gonzalez, Macarena; Carles, Joan. Selective HIF2A Inhibitors in the Management of Clear Cell Renal Cancer and Von Hippel-Lindau-Disease-Associated Tumors. Med Sci (Basel, Switzerland). 11 – 3, 01/01/2023. ISSN 2076-3271
Pestana RC, Serrano C. Analysis of histology-agnostic targets among soft tissue and bone sarcomas in the AACR GENIE database. Front Oncol. 2023 Jan 18;12:1079909. doi: 10.3389/fonc.2022.1079909. eCollection 2022.
RJ Motzer; M Schmidinger; M Eto; C Suarez; R Figlin; Y Liu; R Perini; Y Zhang; DY. Heng. LITESPARK-011: Belzutifan plus lenvatinib vs cabozantinib in advanced renal cell carcinoma after anti-PD-1/PD-L1 therapy. Future Oncol.08/02/2023. ISSN 1479-6694. DOI: 10.2217/fon-2022-0802
Yu, Evan Y.; Piulats, Josep M.; Gravis, Gwenaelle; Fong, Peter C. C.; Todenhoefer, Tilman; Laguerre, Brigitte; Arranz, Jose A.; Oudard, Stephane; Massard, Christophe; Heinzelbecker, Julia; Nordquist, Luke T.; Carles, Joan; Kolinsky, Michael P.; Augustin, Marinela; Gurney, Howard; Tafreshi, Ali; Li, Xin Tong; Qiu, Ping; Poehlein, Christian H.; Schloss, Charles; de Bono, Johann S.Pembrolizumab plus Olaparib in Patients with Metastatic Castration-resistant Prostate Cancer: Long-term Results from the Phase 1b/2 KEYNOTE-365 Cohort A Study (vol 83, pg 15, 2023). Eur Urol. 83 – 3, pp. E87 – E87. 16/02/2023. ISSN 0302-2838, ISSN 1873-7560
Moreno V, Vieito M, Sepulveda JM, Galvao V, Hernández-Guerrero T, Doger B, Saavedra O, Carlo-Stella C, Michot JM, Italiano A, Magagnoli M, Carpio C, Pinto A, Sarmiento R, Amoroso B, Aronchik I, Filvaroff E, Hanna B, Wei X, Nikolova Z, Braña I. BET inhibitor trotabresib in heavily pretreated patients with solid tumors and diffuse large B-cell lymphomas. Nat Commun. 2023 Mar 13;14(1):1359. doi: 10.1038/s41467-023-36976-1. PMID: 36914652 Free PMC article. Clinical Trial.
He W, Xu L, Ding J, Song L, Yang W, Klooster I, Pilco-Janeta DF, Serrano C, Fang H, Jiang G, Wang X, Yu J, Ou WB. Co-targeting of ACK1 and KIT triggers additive anti-proliferative and -migration effects in imatinib-resistant gastrointestinal stromal tumors. Biochim Biophys Acta Mol Basis Dis. 2023 Jun;1869(5):166690. doi: 10.1016/j.bbadis.2023.166690. Epub 2023 Mar 13.
Gillessen S, Bossi A, Davis ID, de Bono J, Fizazi K, James ND, Mottet N, Shore N, Small E, Smith M, Sweeney CJ, Tombal B, Antonarakis ES, Aparicio AM, Armstrong AJ, Attard G, Beer TM, Beltran H, Bjartell A, Blanchard P, Briganti A, Bristow RG, Bulbul M, Caffo O, Castellano D, Castro E, Cheng HH, Chi KN, Chowdhury S, Clarke CS, Clarke N, Daugaard G, De Santis M, Duran I, Eeles R, Efstathiou E, Efstathiou J, Ekeke ON, Evans CP, Fanti S, Feng FY, Fonteyne V, Fossati N, Frydenberg M, George D, Gleave M, Gravis G, Halabi S, Heinrich D, Herrmann K, Higano C, Hofman MS, Horvath LG, Hussain M, Jereczek-Fossa BA, Jones R, Kanesvaran R, Kellokumpu-Lehtinen PL, Khauli RB, Klotz L, Kramer G, Leibowitz R, Logothetis C, Mahal B, Maluf F, Mateo J, Matheson D, Mehra N, Merseburger A, Morgans AK, Morris MJ, Mrabti H, Mukherji D, Murphy DG, Murthy V, Nguyen PL, Oh WK, Ost P, O’Sullivan JM, Padhani AR, Pezaro CJ, Poon DMC, Pritchard CC, Rabah DM, Rathkopf D, Reiter RE, Rubin MA, Ryan CJ, Saad F, Sade JP, Sartor O, Scher HI, Sharifi N, Skoneczna I, Soule H, Spratt DE, Srinivas S, Sternberg CN, Steuber T, Suzuki H, Sydes MR, Taplin ME, Tilki D, Türkeri L, Turco F, Uemura H, Uemura H, Ürün Y, Vale CL, van Oort I, Vapiwala N, Walz J, Yamoah K, Ye D, Yu EY, Zapatero A, Zilli T, Omlin A. Management of patients with advanced prostate cancer-metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022. Eur J Cancer. 2023 May;185:178-215. doi: 10.1016/j.ejca.2023.02.018. Epub 2023 Mar 3. PMID: 37003085.
Moreno V, Vieito M, Sepulveda JM, Galvao V, Hernández-Guerrero T, Doger B, Saavedra O, Carlo-Stella C, Michot JM, Italiano A, Magagnoli M, Carpio C, Pinto A, Sarmiento R, Amoroso B, Aronchik I, Filvaroff E, Hanna B, Wei X, Nikolova Z, Braña I. BET inhibitor trotabresib in heavily pretreated patients with solid tumors and diffuse large B-cell lymphomas. Nat Commun. 2023 Mar 13;14(1):1359. doi: 10.1038/s41467-023-36976-1. PMID: 36914652 Free PMC article. Clinical Trial.
Pérez-Fidalgo JA, Ortega E, Ponce J, Redondo A, Sevilla I, Valverde C, Isern Verdum J, de Alava E, Galera López M, Marquina G, Sebio A. Uterine sarcomas: clinical practice guidelines for diagnosis, treatment, and follow-up, by Spanish group for research on sarcomas (GEIS). Ther Adv Med Oncol. 2023 Mar 28;15:17588359231157645. doi: 10.1177/17588359231157645. PMID: 37007636; PMCID: PMC10052607.
T Powles; M Kockx; A Rodriguez-Vida; I Duran; SJ Crabb; MS Van Der Heijden; B Szabados; AF Pous; G Gravis; UA Herranz; A Protheroe; A Ravaud; D Maillet; MJ Mendez; C Suarez; M Linch; A Prendergast; PJ van Dam; D Stanoeva; S Daelemans; S Mariathasan; JS Tea; K Mousa; R Banchereau; D Castellano. Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial. Nat Med. 29 – 12, pp. 3271. 21/03/2023. DOI: 10.1038/s41591-019-0628-7
C Loo Gan; J Huang; E Pan; W Xie; AL Schmidt; C Labaki; L Meza; G Bouchard; H Li; F Jackson-Spence; C Sánchez-Ruiz; T Powles; SA Kumar; N Weise; WA Hall; BS Rose; B Beuselinck; C Suarez; SK Pal; TK Choueiri; DYC Heng; RR. McKay. Real-world Practice Patterns and Safety of Concurrent Radiotherapy and Cabozantinib in Metastatic Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium. Eur Urol Oncol. 6 – 2, pp. 204 – 211. 01/04/2023. DOI: 10.1016/j.euo.2022.10.004
Serrano C, Bauer S, Gómez-Peregrina D, Kang YK, Jones RL, Rutkowski P, Mir O, Heinrich MC, Tap WD, Newberry K, Grassian A, Shi H, Bialick S, Schöffski P, Pantaleo MA, von Mehren M, Trent JC, George S. Circulating tumor DNA analysis of the phase III VOYAGER trial: KIT mutational landscape and outcomes in patients with advanced gastrointestinal stromal tumor treated with avapritinib or regorafenib. Ann Oncol. 2023 Jul;34(7):615-625. doi: 10.1016/j.annonc.2023.04.006. Epub 2023 Apr 25.
Ruiz-Demoulin S, Trenquier E, Dekkar S, Deshayes S, Boisguérin P, Serrano C, de Santa Barbara P, Faure S. LIX1 Controls MAPK Signaling Reactivation and Contributes to GIST-T1 Cell Resistance to Imatinib. Int J Mol Sci. 2023 Apr 12;24(8):7138. doi: 10.3390/ijms24087138.
Carles, Joan; Medina-Lopez, Rafael A.; Puente, Javier; Gomez-Ferrer, Alvaro; Nebra, Javier Casas; Medina, Maria Isabel Saez; Ribal, Maria J.; Antolin, Alfredo Rodriguez; Alvarez-Ossorio, Jose Luis; Novo, Jose Francisco Suarez; Agut, Cristina Moretones; Srinivasan, Shankar; Ortiz, Jorge; Fizazi, Karim. Darolutamide in Spanish patients with nonmetastatic castration-resistant prostate cancer: ARAMIS subgroup analysis. Fut Oncol. 19 – 12, pp. 819 – 828. Fut Med LTD, 24/05/2023. ISSN 1479-6694, ISSN 1744-8301
Morales-Barrera, Rafael; Villacampa, Guillermo; Vidal, Natalia; Figols, Mariona; Giner, Julia; Bonfill, Teresa; Suarez, Cristina; Diaz, Nely; Mateo, Joaquin; Gonzalez, Macarena; Domenech, Montserrat; Puente, Javier; Carles, Joan. Prevalence of immune-related adverse events and anti-tumor efficacy in advanced/metastatic urothelial carcinoma following immune-checkpoint inhibitor treatment. Clin & Trans Oncol. 25 – 12, pp. 3556 – 3564. SPRINGER INT PUBL AG, 22/05/2023. ISSN 1699-048X, ISSN 1699-3055
C Suárez; JMG Larkin; P Patel; BP Valderrama; A Rodriguez-Vida; H Glen; F Thistlethwaite; C Ralph; G Srinivasan; MJ Mendez-Vidal; R Hartmaier; A Markovets; A Prendergast; B Szabados; K Mousa; T Powles. Phase II Study Investigating the Safety and Efficacy of Savolitinib and Durvalumab in Metastatic Papillary Renal Cancer (CALYPSO). J Clin Oncol.41 – 14, pp. 2493 – 2502. 10/05/2023. ISSN 2394-6520. DOI: 10.1200/JCO.22.01414
Hernando-Calvo A, Mirallas O, Marmolejo D, Saavedra O, Vieito M, Assaf Pastrana JD, Aguilar S, Bescós C, Lorente J, Giralt J, Benavente S, Temprana-Salvador J, Alberola M, Dienstmann R, Garralda E, Felip E, Villacampa G, Brana I. Nutritional status associates with immunotherapy clinical outcomes in recurrent or metastatic head and neck squamous cell carcinoma patients. Oral Oncol. 2023 May;140:106364. doi: 10.1016/j.oraloncology.2023.106364. Epub 2023 Mar 28. PMID: 36989964 Free article.
TK Choueiri; T Powles; L Albiges; M Burotto; C Szczylik; B Zurawski; E Yanez Ruiz; M Maruzzo; A Suarez Zaizar; LE Fein; FA Schutz; DYC Heng; F Wang; F Mataveli; YL Chang; M van Kooten Losio; C Suarez; RJ Motzer. Cabozantinib plus Nivolumab and Ipilimumab in Renal-Cell Carcinoma. N. Engl J Med.388 – 19, pp. 1767 – 1778. 11/05/2023. DOI: 10.1056/NEJMoa2212851
AB McGregor; DM Geynisman; M Burotto; C Suárez; MT Bourlon; PC Barata; S Gulati; S Huo; F Ejzykowicz; SI Blum; V Del Tejo; M Hamilton; JR May; EX Du; A Wu; P Kral; C Ivanescu; A Chin; KA Betts; CH Lee; TK Choueiri; D Cella; C Porta. Matching-adjusted Indirect Comparison of Nivolumab Plus Cabozantinib Versus Pembrolizumab Plus Axitinib in Patients with Advanced Renal Cell Carcinoma. Eur. Urol. Oncol.6 – 3, pp. 339 – 348. 01/06/2023. ISSN 2588-9311. DOI: 10.1016/j.euo.2023.01.012
Suárez C, Vieito M, Valdivia A, González M, Carles J. Med Sci (Basel). Selective HIF2A Inhibitors in the Management of Clear Cell Renal Cancer and Von Hippel-Lindau-Disease-Associated Tumors. 2023 Jun 30;11(3):46. doi: 10.3390/medsci11030046. PMID: 37489462 Free PMC article. Review.
Agarwal, N.; Azad, A. A.; Carles, J. Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial (vol 402, pg 291, 2023). LANCET. 402 – 10398, pp. 290 – 290. 22/07/2023. ISSN 0140-6736, ISSN 1474-547X
MS Ernst; V Navani; JC Wells; F Donskov; N Basappa; C Labaki; SK Pal; L Meza; LA Wood; DS Ernst; B Szabados; RR McKay; F Parnis; C Suarez; T Yuasa; AK Lalani; A Alva; GA Bjarnason; TK Choueiri; DYC Heng. Outcomes for International Metastatic Renal Cell Carcinoma Database Consortium Prognostic Groups in Contemporary First-line Combination Therapies for Metastatic Renal Cell Carcinoma. Eur. Urol 2023; 84 (1): 109 – 116. 07/2023. DOI: 10.1016/j.eururo.2023.01.001
Gelderblom H, Jones RL, Blay JY, George S, von Mehren M, Zalcberg JR, Kang YK, Razak AA, Trent J, Attia S, Le Cesne A, Siontis BL, Goldstein D, Boye K, Sanchez C, Steeghs N, Rutkowski P, Druta M, Serrano C, Somaiah N, Chi P, Harrow B, Becker C, Reichmann W, Sherman ML, Ruiz-Soto R, Heinrich MC, Bauer S; INTRIGUE investigators. Patient-reported outcomes and tolerability in patients receiving ripretinib versus sunitinib after treatment with imatinib in INTRIGUE, a phase 3, open-label study. Eur J Cancer. 2023 Oct;192:113245. doi: 10.1016/j.ejca.2023.113245. Epub 2023 Jul 20. PMID: 37598656 Free article. Clinical Trial.
SK Pal; L Albiges; P Tomczak; C Suárez; MH Voss; G de Velasco; J Chahoud; A Mochalova; G Procopio; H Mahammedi; F Zengerling; C Kim; T Osawa; M Angel; S Gupta; O Khan; G Bergthold; B Liu; M Kalaitzidou; M Huseni; C Scheffold; T Powles; TK Choueiri. Atezolizumab plus cabozantinib versus cabozantinib monotherapy for patients with renal cell carcinoma after progression with previous immune checkpoint inhibitor treatment (CONTACT-03): a multicentre, randomized, open-label, phase 3 trial. Lancet, 402, pp. 185 – 195. 15/07/2023. DOI: 10.1016/S0140-6736(23)00922-4.
Serrano C, Martín-Broto J, Asencio-Pascual JM, López-Guerrero JA, Rubió-Casadevall J, Bagué S, García-Del-Muro X, Fernández-Hernández JÁ, Herrero L, López-Pousa A, Poveda A, Martínez-Marín V. 2023 GEIS Guidelines for gastrointestinal stromal tumors. Ther Adv Med Oncol. 2023 Aug 24;15:17588359231192388. doi: 10.1177/17588359231192388. eCollection 2023. PMID: 37655207 Free PMC article. Review.
Laurence Albiges; Howard Gurney; Vagif Atduev; Cristina Suarez; Miguel A Climent; David Pook; Piotr Tomczak; Philippe Barthelemy; Jae Lyun Lee; Viktor Stus; Thomas Ferguson; Erhan Gokmen; Louis Lacombe; Craig Gedye; Rodolfo F Perini; Manish Sharma; Xiang Peng; Lee Chung-Han. Pembrolizumab plus lenvatinib as first-line therapy for advanced nonclear-cell renal cell carcinoma (KEYNOTE-B61): a single-arm, multicentre, phase 2 trial. The Lancet. 24 – 8, pp. 881 – 891. 01/08/2023. DOI: 10.1016/S1470-2045(23)00276-0
Mellinghoff IK, van den Bent MJ, Blumenthal DT, Touat M, Peters KB, Clarke J, Mendez J, Yust-Katz S, Welsh L, Mason WP, Ducray F, Umemura Y, Nabors B, Holdhoff M, Hottinger AF, Arakawa Y, Sepulveda JM, Wick W, Soffietti R, Perry JR, Giglio P, de la Fuente M, Maher EA, Schoenfeld S, Zhao D, Pandya SS, Steelman L, Hassan I, Wen PY, Cloughesy TF; INDIGO Trial Investigators. Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma. N Engl J Med. 2023 Aug 17;389(7):589-601. doi: 10.1056/NEJMoa2304194. Epub 2023 Jun 4. PMID: 37272516 Clinical Trial.
Tabernero J, Bedard PL, Bang YJ, Vieito M, Ryu MH, Fagniez N, Chadjaa M, Soufflet C, Masson N, Gazzah A. Tusamitamab Ravtansine in Patients with Advanced Solid Tumors: Phase I Study of Safety, Pharmacokinetics, and Antitumor Activity Using Alternative Dosing Regimens. Cancer Res Commun. 2023 Aug 28;3(8):1662-1671. doi: 10.1158/2767-9764.CRC-23-0284. eCollection 2023 Aug. PMID: 37645622 Free PMC article. Clinical Trial.
Di Vito A, Ravegnini G, Gorini F, Aasen T, Serrano C, Benuzzi E, Coschina E, Monesmith S, Morroni F, Angelini S, Hrelia P. The multifaceted landscape behind imatinib resistance in gastrointestinal stromal tumors (GISTs): A lesson from ripretinib. Pharmacol Ther. 2023 Aug; 248:108475. doi: 10.1016/j.pharmthera.2023.108475. Epub 2023 Jun 10.
Martin-Broto J, Valverde C, Hindi N, Vincenzi B, Martinez-Trufero J, Grignani G, Italiano A, Lavernia J, Vallejo A, Tos PD, Le Loarer F, Gonzalez-Campora R, Ramos R, Hernández-Jover D, Gutierrez A, Serrano C, Monteagudo M, Letón R, Robledo M, Moura DS, Martin-Ruiz M, López-Guerrero JA, Cruz J, Fernandez-Serra A, Blay JY, Fumagalli E, Martinez-Marin V. REGISTRI: Regorafenib in first-line of KIT/PDGFRA wild type metastatic GIST: a collaborative Spanish (GEIS), Italian (ISG) and French Sarcoma Group (FSG) phase II trial. Mol Cancer. 2023 Aug 9;22(1):127.
Carreras, Maria-Josep; Tomas-Guillen, Elena; Farriols, Anna; Renedo-Miro, Berta; Valdivia, Carolina; Vidal, Jana; Saura, Cristina; Carles, Joan; Felip, Enriqueta; Gorgas, Maria-Queralt; Tabernero, Josep; Monterde, Josep. Use of Drugs in Clinical Practice and the Associated Cost of Cancer Treatment in Adult Patients with Solid Tumors: A 10-Year Retrospective Cohort Study. Curr Oncol. 30 – 9, pp. 7984 – 8004. MDPI, 01/09/2023. ISSN 1198-0052, ISSN 1718-7729
Pook, David; Geynisman, Daniel M.; Carles, Joan; de Braud, Filippo; Joshua, Anthony M.; Perez-Gracia, Jose Luis; Perez, Casilda Llacer; Shin, Sang Joon; Fang, Bruno; Barve, Minal; Maruzzo, Marco; Bracarda, Sergio; Kim, Miso; Kerloeguen, Yannick; Gallo, Jorge Daniel; Maund, Sophia L.; Harris, Adam; Huang, Kuan-Chieh; Poon, Victor; Sutaria, Dhruvitkumar S.; Gurney, Howard. A Phase Ib, Open-label Study Evaluating the Safety and Efficacy of Ipatasertib plus Rucaparib in Patients with Metastatic Castration-resistant Prostate Cancer. Clin Can Res 2023; 29 – 17, AMER ASSOC CANCER RESEARCH, 01/09/2023. ISSN 1078-0432, ISSN 1557-3265
Serrano C, Álvarez R, Carrasco JA, Marquina G, Martínez-García J, Martínez-Marín V, Sala MÁ, Sebio A, Sevilla I, Martín-Broto J. SEOM-GEIS clinical guideline for gastrointestinal stromal tumors (2022). Clin Transl Oncol. 2023 Sep;25(9):2707-2717. doi: 10.1007/s12094-023-03177-7. Epub 2023 May 2. PMID: 37129716 Free PMC article.
Giacomo Nuvola; Veronica Mollica; Francesco Massari; Cristina Suárez. SEP The future of immunotherapy in advanced renal cell carcinoma: beyond PD-1/PD-L1 inhibitors. Future Medicine. 18/09/2023. DOI: 10.2217/imt-2023-021
Vieito M, Moreno V, Spreafico A, Brana I, Wang JS, Preis M, Hernández T, Genta S, Hansen AR, Doger B, Galvao V, Lenox L, Brown RJ, Kalota A, Mehta J, Pastore F, Patel B, Mistry P, Gu J, Lauring J, Patel MR. Phase 1 Study of JNJ-64619178, a Protein Arginine Methyltransferase 5 Inhibitor, in Advanced Solid Tumors. Clin Cancer Res. 2023 Sep 15;29(18):3592-3602. doi: 10.1158/1078-0432.CCR-23-0092. PMID: 37491846 Clinical Trial.
Hernando-Calvo A, Vila-Casadesús M, Bareche Y, Gonzalez-Medina A, Abbas-Aghababazadeh F, Lo Giacco D, Martin A, Saavedra O, Brana I, Vieito M, Fasani R, Stagg J, Mancuso F, Haibe-Kains B, Han M, Berche R, Pugh TJ, Mirallas O, Jimenez J, Gonzalez NS, Valverde C, Muñoz-Couselo E, Suarez C, Diez M, Élez E, Capdevila J, Oaknin A, Saura C, Macarulla T, Carles Galceran J, Felip E, Dienstmann R, Bedard PL, Nuciforo P, Seoane J, Tabernero J, Garralda E, Vivancos A. A pan-cancer clinical platform to predict immunotherapy outcomes and prioritize immuno-oncology combinations in early-phase trials. Med. 2023 Oct 13;4(10):710-727.e5. doi: 10.1016/j.medj.2023.07.006. Epub 2023 Aug 11. PMID: 37572657 Free article.
Drakaki A, Powles T, Bamias A, Martin-Liberal J, Shin SJ, Friedlander T, Tosi D, Park C, Gomez-Roca C, Joly Lobbedez F, Castellano D, Morales-Barrera R, Moreno-Candilejo I, Fléchon A, Yuen K, Rishipathak D, DuPree K, Young F, Michielin F, Shemesh CS, Steinberg EE, Williams P, Lee JL. Atezolizumab plus Magrolimab, Niraparib, or Tocilizumab versus Atezolizumab Monotherapy in Platinum-Refractory Metastatic Urothelial Carcinoma: A Phase Ib/II Open-Label, Multicenter, Randomized Umbrella Study (MORPHEUS Urothelial Carcinoma). Clin Cancer Res. 2023 Nov 1;29(21):4373-4384.
Kokkali S, Georgaki E, Mandrakis G, Valverde C, Theocharis S. Genomic Profiling and Clinical Outcomes of Targeted Therapies in Adult Patients with Soft Tissue Sarcomas. Cells. 2023 Nov 15;12(22):2632. doi: 10.3390/cells12222632. PMID: 37998367; PMCID: PMC10670373.
Mateo J, de Bono JS, Fizazi K, Saad F, Shore N, Sandhu S, Chi KN, Agarwal N, Olmos D, Thiery-Vuillemin A, Özgüroğlu M, Mehra N, Matsubara N, Young Joung J, Padua C, Korbenfeld E, Kang J, Marshall H, Lai Z, Barnicle A, Poehlein C, Lukashchuk N, Hussain M. Olaparib for the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer and Alterations in BRCA1 and/or BRCA2 in the PROfound Trial. J Clin Oncol. 2023 Nov 14:JCO2300339. doi: 10.1200/JCO.23.00339.
Serrano, Cesar; Rothschild, Sara; Villacampa, Guillermo; Heinrich, Michael C; George, Suzanne; Blay, Jean-Yves; Sicklick, Jason K; Schwartz, Gary K; Rastogi, Sameer; Jones, Robin L; Rutkowski, Piotr; Somaiah, Neeta; Navarro, Victor; Evans, Denisse; Trent, Jonathan C. Rethinking placebos: embracing synthetic control arms in clinical trials for rare tumors. Nat Med 2023; 29 (11): 2689 – 2692
Fizazi, Karim; Azad, Arun A.; Matsubara, Nobuaki; Carles, Joan; Fay, Andre P.; De Giorgi, Ugo; Joung, Jae Young; Fong, Peter C. C.; Voog, Eric; Jones, Robert J.; Shore, Neal D.; Dunshee, Curtis; Zschaebitz, Stefanie; Oldenburg, Jan; Ye, Dingwei; Lin, Xun; Healy, Cynthia G.; Di Santo, Nicola; Laird, A. Douglas; Zohren, Fabian; Agarwal, Neeraj. First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: the phase 3 TALAPRO-2 trial. Nat Med. Nature Portfolio, 04/12/2023. ISSN 1078-8956, ISSN 1546-170X
Font A, Mellado B, Climent MA, Virizuela JA, Oudard S, Puente J, Castellano D, González-Del-Alba A, Pinto A, Morales-Barrera R, Rodriguez-Vida A, Fernandez PL, Teixido C, Jares P, Aldecoa I, Gibson N, Solca F, Mondal S, Lorence RM, Serra J, Real FX. Phase II trial of afatinib in patients with advanced urothelial carcinoma with genetic alterations in ERBB1-3 (LUX-Bladder 1). Br J Cancer. 2023 Dec 15. doi: 10.1038/s41416-023-02513-6.
Hindi N, Razak A, Rosembaum E, Jonczak E, Hamacher R, Rutkowski P, Bhadri VA, Skryd A, Brahmi M, Alshibany A, Jagodzinska-Mucha P, Bauer S, Connolly E, Gelderblom H, Boye K, Henon C, Bae S, Bogefors K, Vincenzi B, Martinez-Trufero J, Lopez-Martin JA, Redondo A, Valverde C, Blay JY, Moura DS, Gutierrez A, Tap W, Martin-Broto J. Efficacy of immune checkpoint inhibitors in alveolar soft-part sarcoma: results from a retrospective worldwide registry. ESMO Open. 2023 Dec;8(6):102045.
Sánchez JC, Picola N, Rodriguez-Vida A, Costa M, Castañeda DM, Márquez MP, Rodriguez JM, Gaya JM, Bravo A, Buisan O, Servian P, Suarez JF, Felip MM, Caparrós MJR, Asensio AA, Vilaseca A. Apalutamide for prostate cancer: Multicentre and multidisciplinary real-world study of 227 patients. Cancer Med. 2023 Dec;12(24):21969-21977.

Projects

De la experiencia a la influencia: programa piloto formativo para pacientes en gobernanza hospitalaria y co-creación en investigación oncológica. Funded by: Asociación Española Contra el Cáncer (AECC). Reference: PCV-2026-1192. Execution period: 07/09/2026 – 06/09/2028. Main beneficiary: VHIO. Associated entity: Grupo Español de Pacientes con Cáncer (GEPAC). VHIO’s Scientific Responsible: Claudia Valverde. Granted amount: 149.490,04 €
Efficacy and safety of treatment of disseminated germ cell tumors with the BEP chemotherapy regimen (bleomycin, etoposide, cisplatin) in patients aged ≥ 40 years compared with efficacy and safety in patients aged ≤ 39 years.
Metastatic tropism in urothelial carcinoma and histological subtypes. Characteristics, Treatments, and Outcomes of Patients with Oligometastatic Urothelial Carcinoma.
Systematic Characterization of the Distinct Immunogenomic Features of Cancers of Unknown Primary (CUPs) to Identify New Therapeutic Opportunities.
IMPaCT-Genomica CUP.

Understanding and addressing LATE-effects of treatment of AYA cancer survivors with AI-based digital phenotyping and non-invasive holistic approach – LATE AYA. PI: Macarena Gonzalez/Claudia. Funded by: European Commission. Reference: 101214326. 01/06/2025-31/05/2030. Valverde
Gene mutation profiling of patients with Metastatic renal cell carcinoma treated with mTOR inhibitors. PI: Cristina Suarez Rodríguez. Funding entity: FERO.
BECA APRO 2019 Dra. C. Suarez. Entity: Associació per la Recerca Oncològica. Duration: from 7/2/2020 to 12/31/2024.
DIVAS-Dissecting VAsculas Sarcomas. PI: Claudia Valverde Morales. Entity: Grupo Español de Investigación en Sarcomas (GEIS). Duration: from 8/6/2020 to 12/31/2024.
Avaluant l’efectivitat de teràpies de precisió dirigides a alteracions genètiques recurrents en Tumors Malignes de la Beina del Nervi Perifèric. PI: Joan Carles Galceran. Entity: MARATÓ TV3. Duration: from 7/1/2020 to 1/31/2024.
Validación del valor predictivo de la firma de expresión génica Vigex-RCC en pacientes con cáncer renal metastásico tratados con combinaciones basadas en inmunoterapia en primera línea. PI: Cristina Suarez Rodríguez. Entity: BRISTOL-MYERS SQUIBB. Duration: from 1/1/2023 to 12/31/2024.
First line randomized study platform to optimize treatment in patients with metastatic renal cell carcinoma. PI: Cristina Suarez Rodríguez. Entity: EUROPEAN COMMISSION. Duration: from 5/1/2023 to 4/30/2028.
Comparison of IO-IO vs IO-TKI strategy in metastic clear cell Renal Cell Carcinoma (CARE1). PI: Cristina Suarez Rodríguez. Entity: Fundación CRIS de Investigación para vencer el Cáncer. Duration: from 3/1/2023 to 2/28/2026.
Defining the Landscape and Clinical Relevance of ATM Defects in Lethal Prostate Cancer. IP: Joaquin Mateo Valderrama. Entity: PROSTATE CANCER FOUNDATION. Duration: from 11/21/2017 to 12/31/2024.
IRONMAN-ES: Estudio prospectivo observacional de parámetros clinicos y biomarcadores en cáncer de próstata avanzado en hospitales de España. IP: Joaquin Mateo Valderrama. Entity: The Movember Group PTY LTD. Duration: from 5/15/2019 to 12/31/2024.
Estudio de la interacción entre las vías de señalización de andrógenos y reparación del ADN en cáncer de próstata metastásico y tratamiento con combinaciones con inhibidores de PARP. IP: Joaquin Mateo Valderrama. Entity: Fundación Científica de la Asociación Española Contra el Cáncer. Duration: from 12/1/2020 to 11/24/2024.
Prostate Cancer genomic evolution and signatures of DNA damage repair deficiencies. IP: Joaquin Mateo Valderrama. Entity: Fundación CRIS de Investigación para vencer el Cáncer. Duration: from 9/1/2021 to 9/1/2026.
RAD51 immunofluorescence to identify homologous recombination deficient (HRD) metastatic prostate cancers in a real-world population. IP: Joaquin Mateo Valderrama. Entity: AstraZeneca Farmacéutica Spain, S.A. Duration: from 11/24/2021 to 8/31/2024.
Real world clinical practice study to assess the feasibility and impact of liquid biopsy-based genomic profiling on treatment decision making for patients with metastatic prostate cancer in Spain. IP: Joaquin Mateo Valderrama & Joan Carles Galceran. Entity: SOLTI. Duration: from 11/24/2022 to 12/31/2024.
Analysis of concurrent KIT and PI3K signaling inhibition as front-line tratment in GIST. IP: César Serrano García. Entity: BAYER PHARMA AG. Duration: from 8/1/2015 to 12/31/2024.
Apoptosis induction of DCC 2618 in imatinib sensitive and imatinib resistant Gist cell lines IP: César Serrano García. Entity: Deciphera Pharmaceuticals, LLC. Duration: from 2/22/2016 to 12/31/2024.
Determinantes clínicos y moleculares de respuesta y progresión a la inhibición de KIT en pacientes con tumores del estroma gastrointestinal (GIST) con respuesta prolongada a Imatinib. IP: César Serrano García. Entity: Grupo Español de Investigación en Sarcomas (GEIS). Duration: from 2/1/2017 to 12/31/2024.
Caracterización del potencial predictivo y terapéutico del FBXO32 como mediador crítico de la señalización oncogénica de KIT/PDGFRA en tumores del estroma gastrointestinal. IP: César Serrano García. Entity: Fundación Mari Paz Jiménez Casado (FMPJC). Duation: from 12/18/2017 to 12/31/2024.
Perfiles de resistencia molecular a la inhibición de KIT/PDGFRA en tumores del estroma gastrointestinal IP: César Serrano García. Entity: Fundación Científica de la Asociación Española Contra el Cáncer. Duration: from 12/1/2020 to 11/30/2024.
Role of centralization of pathological diagnosis and implementation of precision medicine strategies in sarcoma. IP: César Serrano García. Entity: Fundación Científica de la Asociación Española Contra el Cáncer. Duration: from 12/1/2022 to 11/30/2027.